Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 21 - 30 of 412

Press

Comment from Recipharm’s board of directors regarding the public offer from Roar BidCo and correction of error in convertible bond terms

2020.12.14 Read more

Press

Recipharm invests USD 2.5 million in clinical GMP capacity for active pharmaceutical ingredients

2020.12.09 Read more

Press

Recipharm announces signature of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273)

2020.11.24 Read more

Press

Recipharm and Medspray establish joint venture to exploit novel softmist technology for pharmaceutical applications

2020.11.17 Read more

Press

Recipharm invests in its pMDI valves production capacity

2020.11.10 Read more

Press

Recipharm AB publishes its interim report for the third quarter 2020

2020.11.05 Read more

Press

Invitation to the presentation of Recipharm’s interim report for the third quarter 2020

2020.11.02 Read more

Press

Recipharm’s proprietary molecule Erdosteine has been positively tested as part of COVID-19 treatment

2020.10.14 Read more

Press

Recipharm invests EUR 2.6 million in Kaysersberg facility

2020.10.13 Read more

Press

Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR[®]-COV19 (ARCT-021) vaccine candidate

2020.10.06 Read more